Catalyst Wire Dossier Catalyst Wire Dossier

Efgartigimod PH20 SC

efgartigimod alfa · argenx
Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for Efgartigimod PH20 SC, covering 2025-10-23 to 2026-07-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. [Phase 2, Phase 3]

See pricing